DanyelzaActive Ingredient(s): Naxitamab-gqgk
FDA Approved: * November 25, 2020
Pharm Company: * Y-MABS THERAPEUTICS INC
Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy. The most common adverse reactions include infusion-related reactions,... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.